Cancer research unlocks 30-year genetic puzzle

 June 12, 2012 in Cancer (Medical Xpress) -- Scientists at the University of Sussex have solved a 30-year genetic puzzle that could help enhance treatment for certain types of “inherited” cancers. Customized Knockout Mice - More than 90 publications rely on knockout mice produced by Ozgene - www.ozgene.com/knockouts The findings relate to an enzyme that plays an important role in the repair of DNA – the genetic blueprint for all life which in mutated form leads to the uncontrolled reproduction of cells and the development of cancers. The enzyme – PARP1 – was first identified as a DNA damage sensor by Professor Sydney Shall in research undertaken at Sussex in the 1980s. Its discovery led to the development of drugs that blocked the DNA repair mechanism in breast, prostate and ovarian cancers found in people who have a family history of those diseases. But for the past three decades scientists have not known exactly how the enzyme recognised and repaired DNA damage. The Cancer Research UK-funded study by the Genome Damage and Stability Centre at Sussex and  the Adolf Butenandt Institute, University of Munich has now shown, using structural biology, biochemistry and cell imaging techniques, that two PARP1 molecules cooperate with each other to detect the damage and then signal to other molecules to bind together at the damage site. The team’s findings are published online (10 June 2012)  in Nature Structural and Molecular Biology. The team, led by Professor Laurence Pearl and Dr Antony Oliver have now discovered that molecules within the enzyme, known as PARP1, cooperate to identify DNA damage and then signal to other molecules to bind together and repair the damage on site. Professor Laurence Pearl, who is head of Life Sciences at the University of Sussex and who led the research with Dr Antony Oliver, says: “When the PARP1 molecules bind together at the site of DNA damage, they cooperate to generate a large molecular ‘flag’ called polyADP-ribose, that signals to other molecules in the cell to come and repair the broken DNA. “Drugs that stop PARP1 from signaling kill a range of breast, ovarian and prostate cancers in people whose tumours have defects in other DNA repair systems, and who often come from families with a strong genetic predisposition to those diseases. Now we have a clearer idea of how PARP1 actually recognises damaged DNA and fires off its DNA damage signal, we can target this system with far greater precision.” The detailed knowledge of how PARP1 signals DNA damage will greatly assist the development of the next generation of drugs that exploit the genetic changes that cause cancers, to kill them, while sparing normal tissues and causing far fewer side effects.